FR19C1031I2 - Modification du facteur fviii en fonction du site - Google Patents

Modification du facteur fviii en fonction du site

Info

Publication number
FR19C1031I2
FR19C1031I2 FR19C1031C FR19C1031C FR19C1031I2 FR 19C1031 I2 FR19C1031 I2 FR 19C1031I2 FR 19C1031 C FR19C1031 C FR 19C1031C FR 19C1031 C FR19C1031 C FR 19C1031C FR 19C1031 I2 FR19C1031 I2 FR 19C1031I2
Authority
FR
France
Prior art keywords
site
modification
factor depending
fviii factor
fviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1031C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Healthcare LLC
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36337298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR19C1031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of FR19C1031I1 publication Critical patent/FR19C1031I1/fr
Application granted granted Critical
Publication of FR19C1031I2 publication Critical patent/FR19C1031I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
FR19C1031C 2004-11-12 2019-05-07 Modification du facteur fviii en fonction du site Active FR19C1031I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62727704P 2004-11-12 2004-11-12
PCT/US2005/041205 WO2006053299A2 (en) 2004-11-12 2005-11-14 Site-directed modification of fviii

Publications (2)

Publication Number Publication Date
FR19C1031I1 FR19C1031I1 (pm) 2019-06-28
FR19C1031I2 true FR19C1031I2 (fr) 2020-06-05

Family

ID=36337298

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1031C Active FR19C1031I2 (fr) 2004-11-12 2019-05-07 Modification du facteur fviii en fonction du site

Country Status (32)

Country Link
US (4) US7632921B2 (pm)
EP (9) EP3243833B1 (pm)
JP (5) JP2008524117A (pm)
KR (7) KR101243564B1 (pm)
CN (6) CN105753968A (pm)
AU (1) AU2005304622B2 (pm)
BE (1) BE2019C523I2 (pm)
BR (2) BRPI0517795B8 (pm)
CA (1) CA2586379C (pm)
CY (3) CY1119292T1 (pm)
DK (3) DK2363414T3 (pm)
ES (4) ES2930143T3 (pm)
FR (1) FR19C1031I2 (pm)
HN (1) HN2007015683A (pm)
HR (2) HRP20070268B1 (pm)
HU (5) HUE059193T2 (pm)
IL (3) IL182903A (pm)
LT (5) LT1824988T (pm)
LU (1) LUC00118I2 (pm)
MA (1) MA29663B1 (pm)
MX (3) MX350293B (pm)
NL (1) NL300989I2 (pm)
NO (3) NO345800B1 (pm)
NZ (1) NZ555032A (pm)
PH (2) PH12014500352B1 (pm)
PL (3) PL1824988T3 (pm)
PT (4) PT3130601T (pm)
RU (1) RU2423380C2 (pm)
SI (4) SI3130601T1 (pm)
UA (1) UA95225C2 (pm)
WO (1) WO2006053299A2 (pm)
ZA (1) ZA200703696B (pm)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
MXPA06015234A (es) * 2004-06-30 2007-11-22 Nektar Therapeutics Al Corp Conjugados de fraccion polimero-factor ix.
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
JP5948627B2 (ja) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー 線維芽細胞成長因子（ｆｇｆ）のリモデリングと糖質ペグ化
BRPI0517795B8 (pt) 2004-11-12 2021-05-25 Bayer Healthcare Llc conjugado apresentando atividade pró-coagulante de fator viii, seu uso, métodos para sua preparação e para peguilação sítio-dirigida de uma muteína de fator viii, e composição farmacêutica
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006134173A2 (en) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
RU2008145084A (ru) * 2006-05-24 2010-06-27 Ново Нордиск Хелс Кеа Аг (Ch) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
US20080248959A1 (en) 2006-07-21 2008-10-09 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
JP2010505874A (ja) 2006-10-03 2010-02-25 ノヴォ ノルディスク アー／エス ポリペプチドコンジュゲートの精製方法
EP3323430A1 (en) 2006-12-15 2018-05-23 Baxalta GmbH Factor viia-(poly)sialic acid conjugate having prolonged in vivo half-life
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
CN101778859B (zh) 2007-06-12 2014-03-26 诺和诺德公司 改良的用于生产核苷酸糖的方法
CA2704234A1 (en) * 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
CN103497246B (zh) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 缀合的因子viii分子
JP5997443B2 (ja) 2008-05-16 2016-09-28 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 標的化凝固因子およびそれを使用する方法
JP5674650B2 (ja) * 2008-06-04 2015-02-25 バイエル・ヘルスケア・エルエルシー フォン・ヴィレブランド病の処置のためのｆｖｉｉｉ変異タンパク質
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
WO2010019263A2 (en) * 2008-08-15 2010-02-18 Genzyme Corporation Soluble flt constructs for treating cancers
DK2349342T3 (en) * 2008-10-17 2018-10-08 Baxalta GmbH MODIFIED BLOOD FACTORS INCLUDING A LOW DEGREE OF WATER SOLUBLE POLYMER
WO2010062768A1 (en) * 2008-11-03 2010-06-03 Bayer Healthcare Llc Method for the treatment of hemophilia
WO2010060081A1 (en) * 2008-11-24 2010-05-27 Bayer Healthcare Llc Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
EP2398822B1 (en) * 2009-02-19 2013-01-02 Novo Nordisk A/S Modification of factor viii
PL2408800T3 (pl) * 2009-03-20 2016-11-30 Sposób wytwarzania koniugatu miejscowo-specyficznego, fizjologicznie aktywnego polipeptydu
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
NZ623810A (en) 2009-07-27 2015-10-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
DK2459224T3 (en) 2009-07-27 2016-07-25 Baxalta GmbH Blodstørkningsproteinkonjugater
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2459226B1 (en) 2009-07-27 2016-06-29 Lipoxen Technologies Limited Glycopolysialylation of proteins other than blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP3222287A1 (en) 2009-08-24 2017-09-27 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
ME02964B (me) 2009-12-06 2018-07-20 Himerni i hibridni polipeptidi faktora viii-fc, i postupci za njihovu upotrebu
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
CN105524164A (zh) 2010-02-16 2016-04-27 诺沃—诺迪斯克有限公司 具有降低的vwf结合的因子viii分子
US9254336B2 (en) * 2010-02-21 2016-02-09 Bayer Healthcare Llc Method for activation and conjugation of biomolecules
KR20200067958A (ko) 2010-04-15 2020-06-12 코디악 사이언시스 인코포레이티드 고분자량 쌍성이온-함유 중합체
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) * 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
KR101948337B1 (ko) * 2010-11-05 2019-02-14 박스알타 인코퍼레이티드 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체
RU2013131911A (ru) * 2010-12-16 2015-01-27 Ново Нордиск А/С Водный раствор фактора viii
EA032056B1 (ru) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты)
US20120329127A1 (en) * 2011-05-27 2012-12-27 Baxter Healthcare S.A. Therapeutic proteins with increased half-life and methods of preparing same
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
KR102110736B1 (ko) 2011-07-08 2020-05-14 바이오버라티브 테라퓨틱스 인크. Viii 인자 키메라 및 하이브리드 폴리펩타이드, 그리고 이들의 사용 방법
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
KR20130049671A (ko) * 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
NZ628014A (en) * 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
AU2012327217B2 (en) 2012-02-15 2016-05-12 Bioverativ Therapeutics Inc. Factor VIII compositions and methods of making and using same
EP2666782A1 (en) 2012-05-22 2013-11-27 Imnate Sarl Coagulation factor VIII with reduced immunogenicity.
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
HK1213767A1 (zh) 2012-10-18 2016-07-15 Bioverativ Therapeutics Inc. 使用固定劑量凝血因子的方法
US20150266944A1 (en) 2012-10-30 2015-09-24 Biogen Idec Ma Inc. Methods of Using FVIII Polypeptide
RS60003B1 (sr) 2013-03-15 2020-04-30 Bioverativ Therapeutics Inc Formulacije polipeptida faktora viii
US20160030524A1 (en) * 2013-03-15 2016-02-04 Bayer Healthcare Llc Recombinant factor viii formulations
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
RU2683039C2 (ru) 2013-04-18 2019-03-26 Ново Нордиск А/С Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
EP4108254A1 (en) 2013-08-14 2022-12-28 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
US10702608B2 (en) 2013-09-08 2020-07-07 Kodiak Sciences Inc. Factor VIII zwitterionic polymer conjugates
KR20160090810A (ko) * 2013-10-22 2016-08-01 디비브이 테크놀로지스 (소시에떼 아노님) 혈액 인자에 대한 관용 유도에 의한 혈우병의 치료 방법
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
RU2546297C1 (ru) * 2013-11-19 2015-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Средство, улучшающее реологические свойства крови
US10325687B2 (en) 2013-12-06 2019-06-18 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
ES2688144T3 (es) 2014-01-20 2018-10-31 Octapharma Ag Procedimiento de fabricación de Factor VIII que tiene una relación mejorada de FVIII:C/FVIII:AG
NZ722391A (en) 2014-02-04 2022-12-23 Biogen Ma Inc Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications
WO2015132724A1 (en) 2014-03-05 2015-09-11 Pfizer Inc. Improved muteins of clotting factor viii
MA39779A (fr) 2014-03-24 2017-02-01 Biogen Ma Inc Formulations de facteur ix lyophilisées
WO2015154090A1 (en) * 2014-04-04 2015-10-08 Bloodworks Routine laboratory and point-of-care (poc) testing for hemostasis
PE20161326A1 (es) 2014-04-10 2016-12-11 Bayer Healthcare Llc Formulacion en polvo de medio de compuesto y metodo de preparacion de medio liquido para cultivo celular
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
KR20170026580A (ko) 2014-07-02 2017-03-08 씨에스엘 리미티드 변형된 폰 빌레브란트 인자
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
AU2016231327B2 (en) 2015-03-06 2018-08-09 CSL Behring Lengnau AG Modified von Willebrand factor having improved half-life
CA2986626A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Truncated von willebrand factor polypeptides for treating hemophilia
CA2986625A1 (en) 2015-05-22 2016-12-01 Csl Behring Recombinant Facility Ag Methods for preparing modified von willebrand factor
BR112018002150A2 (pt) 2015-08-03 2018-09-18 Bioverativ Therapeutics Inc proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
WO2017117630A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated von willebrand factor
WO2017117631A1 (en) 2016-01-07 2017-07-13 Csl Limited Mutated truncated von willebrand factor
US20230151078A1 (en) * 2016-06-24 2023-05-18 Mogam Instiitute For Biomedical Research Recombinant single-chain fviii and chemical conjugate thereof
SG10201912768YA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
KR20190085021A (ko) 2016-11-11 2019-07-17 체에스엘 베링 렝나우 아게 혈우병을 치료하기 위한 절단된 폰 빌레브란트 인자 폴리펩타이드
AR110079A1 (es) 2016-11-16 2019-02-20 Bayer Healthcare Llc Factor viii direccionado a los glóbulos rojos y método para su uso
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US12161696B2 (en) 2016-12-02 2024-12-10 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
MA47416A (fr) 2017-01-31 2019-12-11 Bioverativ Therapeutics Inc Protéine de fusion du facteur ix et procédés de fabrication et d'utilisation associés
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
EP4585260A3 (en) 2018-05-18 2025-08-13 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021091881A1 (en) * 2019-11-04 2021-05-14 The Trustees Of Columbia University In The City Of New York High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof
US20220403005A1 (en) * 2019-12-06 2022-12-22 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
AU2473388A (en) * 1987-11-16 1989-06-22 Scripps Clinic And Research Foundation Treatment of factor viii inhibitors
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
EP1652534A3 (en) 1992-10-02 2007-05-02 Genetics Institute, LLC Composition comprising coagulation factor VIII formulation, process for its preparation and use of a surfactant as stabilizer
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
AU685187B2 (en) 1993-10-29 1998-01-15 Incyte Pharmaceuticals, Inc. Chimeric proteins including protease nexin-1 variants
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
BE1008491A3 (fr) * 1994-07-14 1996-05-07 Croix Rouge De Belgique Depart Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci.
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
WO1997001197A1 (en) * 1995-06-21 1997-01-09 Motorola Inc. Method and antenna for providing an omnidirectional pattern
WO1997003195A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered protease sites
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403438B (de) 1996-05-24 1998-02-25 Immuno Ag Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität
US6458563B1 (en) * 1996-06-26 2002-10-01 Emory University Modified factor VIII
AU3908597A (en) * 1996-08-02 1998-02-25 Ortho-Mcneil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1881005B1 (en) 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
CN1113656C (zh) * 1997-10-17 2003-07-09 丰收技术股份有限公司 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物
EP0922446A1 (en) 1997-12-03 1999-06-16 Applied Research Systems Ars Holding N.V. Solution-phase site-specific preparation of GRF-PEG conjugates
CA2329768C (en) 1998-04-27 2008-06-10 Opperbas Holding B.V. Pharmaceutical composition comprising factor viii and neutral liposomes
US6759216B1 (en) 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
DK1129186T4 (da) 1998-11-10 2017-02-06 Stichting Sanquin Bloedvoorziening Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
CN1210400C (zh) * 1999-01-14 2005-07-13 博尔德生物技术公司 制备含游离半胱氨酸残基的蛋白质的方法
AU5282200A (en) 1999-05-24 2000-12-12 American National Red Cross, The Methods of reducing factor viii clearance and compositions therefor
EP2319541A1 (en) * 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
KR100638184B1 (ko) 2000-09-19 2006-10-26 에모리 유니버시티 변형된 인자 ⅷ
AU2002248329B2 (en) 2001-01-12 2007-06-28 The American National Red Cross Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
AU2002249096B2 (en) * 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002098454A2 (en) 2001-05-31 2002-12-12 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
EP1572889B1 (en) 2001-10-05 2008-12-17 Expression Therapeutics, LLC Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
ES2319758T3 (es) 2002-04-18 2009-05-12 Merck Patent Gmbh Factor viii modificado.
US8003117B2 (en) 2002-11-20 2011-08-23 Nof Corporation Polyalkylene glycol derivative and modified bio-related substance
JP4412461B2 (ja) 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
KR101031206B1 (ko) 2002-12-31 2011-04-27 넥타르 테라퓨틱스 말레암산 중합체 유도체 및 이의 바이오컨쥬게이트
AU2003300133B2 (en) 2002-12-31 2008-11-13 Nektar Therapeutics Hydrolytically stable maleimide-terminated polymers
AU2004204136B2 (en) 2003-01-06 2008-10-09 Nektar Therapeutics Thiol-selective water-soluble polmer derivatives
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
US20040180054A1 (en) * 2003-03-13 2004-09-16 Hanmi Pharm. Co., Ltd. Physiologically active polypeptide conjugate having prolonged in vivo half-life
US20050176108A1 (en) * 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
AU2004238869B2 (en) * 2003-05-12 2009-06-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
EP2644206B1 (en) 2003-05-23 2019-04-03 Nektar Therapeutics PEG derivatives containing two PEG chains
EP1502921A1 (en) 2003-07-29 2005-02-02 ZLB Behring GmbH Recombinant mutated human factor VIII (FVIII) with improved stability
EP1682106A4 (en) 2003-10-30 2008-06-11 Univ Emory MODIFIED FVIII WITH REDUCED IMMUNOGENICITY BY MUTAGENESIS OF A2 AND C2 EPITOPES
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
DE602004026474D1 (de) 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
WO2006027111A1 (en) 2004-09-06 2006-03-16 Zlb Behring Gmbh Modified coagulation factor viii with enhanced stability
BRPI0517795B8 (pt) 2004-11-12 2021-05-25 Bayer Healthcare Llc conjugado apresentando atividade pró-coagulante de fator viii, seu uso, métodos para sua preparação e para peguilação sítio-dirigida de uma muteína de fator viii, e composição farmacêutica
WO2006103298A2 (en) 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
MX2008012600A (es) * 2006-03-31 2008-12-12 Baxter Int Factor viii pegilado.

Also Published As

Publication number Publication date
SI1824988T1 (sl) 2017-11-30
CN105148287A (zh) 2015-12-16
EP2772500B1 (en) 2019-12-25
EP3130601A1 (en) 2017-02-15
PH12014500352A1 (en) 2015-07-20
AU2005304622B2 (en) 2012-03-29
CN101124331B (zh) 2013-04-24
EP2371856B1 (en) 2022-05-18
US9364520B2 (en) 2016-06-14
HUE050542T2 (hu) 2020-12-28
EP2371856A3 (en) 2012-03-14
ES2930159T3 (es) 2022-12-07
HUE033776T2 (en) 2018-01-29
DK2371856T3 (en) 2022-08-08
US7632921B2 (en) 2009-12-15
EP3323829A1 (en) 2018-05-23
CN103214569A (zh) 2013-07-24
BRPI0517795B8 (pt) 2021-05-25
JP2017101028A (ja) 2017-06-08
JP6487895B2 (ja) 2019-03-20
KR20140019489A (ko) 2014-02-14
LT3130601T (lt) 2020-09-10
EP1824988A2 (en) 2007-08-29
KR101483917B1 (ko) 2015-01-16
PL2371856T3 (pl) 2022-08-22
IL182903A0 (en) 2007-08-19
CN105753968A (zh) 2016-07-13
WO2006053299A3 (en) 2006-08-24
MX350293B (es) 2017-09-04
NO344606B1 (no) 2020-02-10
CY1123384T1 (el) 2021-12-31
HK1218718A1 (zh) 2017-03-10
IL182903A (en) 2014-09-30
EP2363414A2 (en) 2011-09-07
ES2930143T3 (es) 2022-12-07
JP6559642B2 (ja) 2019-08-14
JP2008524117A (ja) 2008-07-10
LT2363414T (lt) 2022-10-25
AU2005304622A1 (en) 2006-05-18
KR20140091618A (ko) 2014-07-21
HUS1900026I1 (hu) 2022-04-28
UA95225C2 (ru) 2011-07-25
EP2363414B1 (en) 2022-05-18
CN103102406B (zh) 2015-05-27
US20060115876A1 (en) 2006-06-01
CY2019024I1 (el) 2019-11-27
KR101468345B1 (ko) 2014-12-03
ES2821832T3 (es) 2021-04-27
CY2019024I2 (el) 2019-11-27
EP2363414A3 (en) 2012-03-21
JP2015134780A (ja) 2015-07-27
RU2007121517A (ru) 2008-12-20
EP3130601B1 (en) 2020-07-15
RU2423380C2 (ru) 2011-07-10
CN101124331A (zh) 2008-02-13
ZA200703696B (en) 2008-08-27
US9096656B2 (en) 2015-08-04
NO20072997L (no) 2007-06-27
WO2006053299A2 (en) 2006-05-18
KR20120136413A (ko) 2012-12-18
PT1824988T (pt) 2017-07-21
JP2013067621A (ja) 2013-04-18
KR20160105928A (ko) 2016-09-07
BE2019C523I2 (pm) 2025-02-10
IL234433B (en) 2019-11-28
EP3323829B1 (en) 2020-07-15
KR101654011B1 (ko) 2016-09-05
KR20180110192A (ko) 2018-10-08
PT2363414T (pt) 2022-08-04
LT2371856T (lt) 2022-08-25
SI2371856T1 (sl) 2022-09-30
NL300989I2 (nl) 2019-11-28
CN103214569B (zh) 2016-12-28
BRPI0517795A8 (pt) 2018-12-26
LUC00118I1 (pm) 2019-05-13
EP3153181A1 (en) 2017-04-12
CA2586379C (en) 2012-04-03
MA29663B1 (fr) 2008-08-01
HUE060016T2 (hu) 2023-01-28
DK2363414T3 (da) 2022-08-08
CY1119292T1 (el) 2018-02-14
NL300989I1 (nl) 2019-05-22
PT3130601T (pt) 2020-10-01
PL2363414T3 (pl) 2022-09-05
KR101904630B1 (ko) 2018-10-04
BR122016022033B8 (pt) 2021-05-25
PH12019501613A1 (en) 2020-09-14
JP6018238B2 (ja) 2016-11-02
KR20070110260A (ko) 2007-11-16
PL1824988T3 (pl) 2018-01-31
HUE059193T2 (hu) 2022-10-28
SI3130601T1 (sl) 2020-11-30
LT1824988T (lt) 2017-10-25
KR20130036780A (ko) 2013-04-12
BR122016022033B1 (pt) 2021-03-02
EP3243833A1 (en) 2017-11-15
CA2586379A1 (en) 2006-05-18
NO20210454A1 (no) 2007-06-27
SI2363414T1 (sl) 2022-09-30
HN2007015683A (es) 2011-07-11
FR19C1031I1 (pm) 2019-06-28
HRP20070268A2 (hr) 2007-09-30
NZ555032A (en) 2010-02-26
PH12014500352B1 (en) 2019-09-25
EP2371856A2 (en) 2011-10-05
LUC00118I2 (pm) 2019-12-27
EP1824988A4 (en) 2008-12-31
HRP20180481A2 (hr) 2018-06-29
MX392760B (es) 2025-03-24
MX2007005466A (es) 2007-10-19
LTC1824988I2 (lt) 2021-02-25
EP3243834A1 (en) 2017-11-15
HRP20180481B1 (hr) 2022-02-18
IL232540A (en) 2017-08-31
LTPA2019509I1 (lt) 2019-08-26
HK1182121A1 (en) 2013-11-22
NO20200044A1 (no) 2007-06-27
BRPI0517795B1 (pt) 2020-03-31
DK1824988T3 (en) 2017-08-07
NO345800B1 (no) 2021-08-09
US20130274445A1 (en) 2013-10-17
HK1117875A1 (en) 2009-01-23
PT2371856T (pt) 2022-08-12
EP1824988B1 (en) 2017-04-19
IL232540A0 (en) 2014-06-30
HRP20070268B1 (hr) 2018-04-20
JP6109523B2 (ja) 2017-04-05
ES2633916T3 (es) 2017-09-26
KR101243564B1 (ko) 2013-03-27
CN105148287B (zh) 2019-07-09
JP2017105773A (ja) 2017-06-15
US20160051633A1 (en) 2016-02-25
US20100081615A1 (en) 2010-04-01
CN107082806A (zh) 2017-08-22
EP3243833B1 (en) 2020-06-17
CN103102406A (zh) 2013-05-15
BRPI0517795A (pt) 2008-10-21
EP2772500A1 (en) 2014-09-03

Similar Documents

Publication Publication Date Title
FR19C1031I2 (fr) Modification du facteur fviii en fonction du site
DK1667992T3 (da) Quinazolinderivater
DE502004004258D1 (de) Teleskopierbare lenkwelle
DE502004001642D1 (de) Teleskopschiene
EP1795050A4 (en) DISPLAY
ATE442044T1 (de) Herbizid-safener-kombination
EP1756698A4 (en) DISPLAY DEVICE
SE0401060L (sv) Teleskopanordning
DE502004006772D1 (de) Wirkwerkzeug-Barre
EP1739543A4 (en) SCREEN TRANSITION CONTROL DEVICE
DE502005000496D1 (de) Verstellvorrichtung
DE602005002416T8 (de) Zündanordnung
EP1784688A4 (en) REAR SCREEN
FR2857683B1 (fr) Kiosque telescopique
ATA9992004A (de) Hydrant
DE112005002293A5 (de) Verstelleinrichtung
ATA152004A (de) Lesepult
DE502005004692D1 (de) Massageaufsatz
ITMI20042061A1 (it) Vaglio
AT7945U3 (de) Freitragende treppe
FI20031936A0 (fi) Seula
SE0302926D0 (sv) Skärmlänsa
FIU20050035U0 (fi) Pikalukitsin
AT500956B8 (de) Personenschleuse
FI6236U1 (fi) Kaihdinjärjestely